[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:dedifferentiated-liposarcoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":65,"states":66},"Dedifferentiated Liposarcoma",9,[7,15,22,28,34,40,47,53,59],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06843967","A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:19:26.493949Z","2026-05-05T02:43:27.666715Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT05607095","A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma",[19],"Phase 1","2026-08-26T02:18:51.009190Z","2026-07-19T19:36:05.123927Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT06975293","STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas",[11],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:29.479024Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT06578624","Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors",[11],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:28.546807Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":38,"content_modified":39},"NCT06498648","Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma",[11],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:28.316488Z",{"nct_id":41,"title":42,"phases":43,"status":12,"updated_at":45,"content_modified":46},"NCT06422806","Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas",[44],"Phase 3","2026-08-26T02:16:23.080181Z","2026-05-05T02:43:27.931275Z",{"nct_id":48,"title":49,"phases":50,"status":12,"updated_at":51,"content_modified":52},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[11],"2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":54,"title":55,"phases":56,"status":12,"updated_at":57,"content_modified":58},"NCT05711615","Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma",[19],"2026-08-26T02:19:30.857183Z","2026-07-05T05:32:16.811405Z",{"nct_id":60,"title":61,"phases":62,"status":12,"updated_at":63,"content_modified":64},"NCT06789172","A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors",[19],"2026-08-26T02:16:18.872924Z","2026-07-05T05:32:16.698119Z",[],[67,71,75,78,81,85,88,91,94],{"state":68,"count":69,"slug":70},"Texas",5,"texas",{"state":72,"count":73,"slug":74},"California",4,"california",{"state":76,"count":73,"slug":77},"Massachusetts","massachusetts",{"state":79,"count":73,"slug":80},"New York","new-york",{"state":82,"count":83,"slug":84},"Illinois",3,"illinois",{"state":86,"count":83,"slug":87},"Michigan","michigan",{"state":89,"count":83,"slug":90},"Missouri","missouri",{"state":92,"count":83,"slug":93},"Ohio","ohio",{"state":95,"count":83,"slug":96},"Virginia","virginia"]